Comparing statin strengths: why the milligram number is not the whole story
Statin decisions are based on expected LDL cholesterol lowering, not the milligram numbers printed on different products. The current NICE lipid guideline sets a primary prevention aim of a greater than 40% reduction in non-HDL cholesterol after treatment. A smaller figure on one statin can represent the same treatment intensity as a larger figure on another, because the ingredients differ in absorption, metabolism and interactions. The prescribed ingredient, follow-up blood test, other medicines and individual risk matter more than the number on the box.
Key takeaways
- Milligrams describe the quantity of one ingredient; they are not a potency scale across atorvastatin, rosuvastatin and simvastatin.
- NICE groups statin regimens by expected LDL-lowering intensity and sets a primary prevention aim of a greater than 40% reduction in non-HDL cholesterol; an individual’s measured response still matters.
- HealthHub’s atorvastatin leaflet and the FDA simvastatin label show that interactions, liver or kidney function, pregnancy and previous adverse effects can matter more than a comparison chart.
Why can a lower milligram number be a stronger statin?
A milligram is a unit of mass, not a score. The same number of milligrams of atorvastatin and of rosuvastatin are amounts of two different molecules. Their absorption, transport into the liver, metabolism and effect on LDL receptors differ. Reading a larger number as “stronger” is like comparing two liquids by spoonful without asking what each liquid contains.
Guidelines classify statin-and-strength combinations as low, medium or high intensity according to expected LDL reduction. NICE’s lipid guideline, published on 14 December 2023, places some atorvastatin and rosuvastatin regimens in the same high-intensity band and commonly used simvastatin regimens in a medium-intensity band. Those bands are population-level summaries; they do not convert one tablet into an equivalent of another.
What does “high-intensity” actually mean?
In NICE’s lipid guideline, intensity describes average LDL-lowering effect in study populations, not the exact reduction in one person. A high-intensity option is not automatically appropriate, and two medicines in the same band are not automatically interchangeable. For primary prevention, NICE sets the aim as a greater than 40% reduction in non-HDL cholesterol, and the actual response still needs a follow-up lipid test.
| Label or result | What it can tell you | What it cannot tell you |
|---|---|---|
| Milligrams on one statin | The amount of that ingredient | How it compares directly with a different statin |
| Guideline intensity band | Expected LDL-lowering range in populations | One person’s exact response or suitability |
| Follow-up lipid result | The observed change after treatment | Whether every future result will be identical |
| Brand name | Which marketed product is supplied | Ingredient, strength or formulation without checking the label |
Clinicians use the lipid profile before treatment, the target reduction and the result after treatment. NICE’s primary prevention aim is a greater than 40% reduction in non-HDL cholesterol, and its sections on optimising statin treatment and assessing response focus on the measured result, not the printed strength.
Are atorvastatin, rosuvastatin and simvastatin interchangeable?
No automatic substitution should be inferred. They belong to the same medicine class and all reduce LDL cholesterol, but they are distinct ingredients. Atorvastatin, rosuvastatin and simvastatin have different intensity ranges, metabolic pathways, interaction profiles and prescribing constraints.
This distinction matters when a prescriber changes treatment and the new label shows a smaller number; that number is not a sign that the regimen has been automatically reduced. HealthHub’s atorvastatin leaflet advises people not to stop taking the medicine without checking with a healthcare professional, because stopping can raise the LDL-cholesterol level again. An online equivalence chart cannot perform that assessment. It summarises expected population LDL effects without accounting for the original prescribing decision, and no such chart makes two statin tablets exchangeable.
Differences can also appear between a statin alone and a combination product. A tablet containing a statin plus another lipid-lowering ingredient cannot be compared with a statin-only tablet by looking at the statin milligrams alone.
Why might the same statin work differently for two people?
Expected intensity is an average. Baseline LDL level, adherence, underlying lipid disorder, diet, other health conditions and biological variation can influence the measured response. NICE advises measuring total cholesterol and HDL cholesterol before treatment, and excluding secondary causes such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome. If the result changes less than expected, the guideline directs attention to adherence, interactions and secondary causes rather than a simple potency problem.
Side effects are not a potency meter. NICE advises that the risk of muscle pain, tenderness or weakness with statins is small and severe muscle adverse effects such as rhabdomyolysis are extremely low. In high-intensity statin studies, around 16% of people reported muscle pain, but only about 1 in 12 were judged likely due to the statin. Symptoms do not prove that another statin would be equivalent, and their absence does not prove a regimen is ineffective.
What changes the answer?
The clinically relevant comparison changes with the purpose of treatment. Primary prevention, established cardiovascular disease and inherited lipid disorders do not carry the same baseline risk or treatment goals.
Kidney or liver function affects choice, precautions and monitoring. Specific interactions are ingredient-dependent. The FDA ZOCOR label lists strong CYP3A4 inhibitors, select azole antifungals, macrolide antibiotics, antiviral medicines and nefazodone among interacting drugs, while HealthHub advises against grapefruit and red yeast rice with atorvastatin. Pregnancy, pregnancy planning or breastfeeding also require a specific discussion: NICE states that statins are contraindicated in pregnancy and should be stopped three months before attempting to conceive. Previous adverse effects matter more than an online ranking, because the symptom, timing, laboratory findings and response to clinical assessment are what a clinician uses.
Which warning signs need prompt assessment?
Seek prompt medical advice for unexplained muscle pain, tenderness or weakness, especially if it is severe or accompanied by fever, marked tiredness or dark urine. Yellowing of the skin or eyes, unusually pale stools, dark urine or significant upper-abdominal discomfort also need assessment. Call emergency services for symptoms of a heart attack or stroke; a statin does not make new chest pain, facial droop, arm weakness or speech difficulty safe to watch at home.
For a medicine review, bring the exact product labels, a current medicines and supplements list, and any available lipid results. HealthHub’s atorvastatin leaflet says to tell a healthcare professional about pregnancy, planning a baby, breastfeeding, liver or kidney problems, and any allergy to this medicine or other statins. Ask which medicines, supplements and foods such as grapefruit juice may interfere with that specific ingredient. NICE advises checking the patient information leaflet, a pharmacist or a prescriber before starting other drugs or supplements. Do not use an intensity table to change or exchange statins yourself.
Sources
- NICE: Cardiovascular disease: risk assessment and reduction, including lipid modification. Guideline reference NG238, published 14 December 2023.
- Singapore HealthHub: Atorvastatin. Medication information leaflet, last reviewed 22 May 2026.
- FDA: ZOCOR (simvastatin) prescribing information. Revised August 2023.
- Reddit r/Cholesterol: Atorvastatin and Rosuvastatin change? Used only as a reader-question signal, not medical evidence.
